Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 4/2013

01-08-2013 | Original Article

The clinical features and prognosis of phyllodes tumors: a single institution experience in Taiwan

Authors: Chin-Chan Lin, Hui-Wen Chang, Chen-Yuan Lin, Chang-Fang Chiu, Shin-Pen Yeh

Published in: International Journal of Clinical Oncology | Issue 4/2013

Login to get access

Abstract

Background and objectives

The aim of this study was to document the clinical and pathological features of a single institutional series of Asian patients with phyllodes tumors, and to determine the prognosis, the adequate management and the predictive histological features.

Methods

The clinical data were retrospectively studied from the medical records and the pathological data from the Department of Pathology were utilized to identify 33 patients diagnosed with phyllodes tumors between 2003 and 2010.

Results

Eight patients had benign tumors, 13 borderline and 12 malignant. Nine patients (27 %) had recurrence. No patients classified as benign phyllodes tumors had recurrence, but those with malignant phyllodes tumors had a high recurrence rate (41 %). The 5-year disease-free survival was 59 %. The 5-year overall survival was 81 %. The width of surgical margin was not related to disease recurrence and stromal overgrowth was the only prognostic factor in terms of disease-free survival and overall survival.

Conclusions

The phyllodes tumors of borderline and malignant classification in Asian patients had a high recurrence rate. Clinical and pathological factors, except for stromal overgrowth, cannot predict disease recurrence. Further molecular research is warranted.
Literature
1.
Chaney AW, Pollack A, McNeese MD et al (2000) Primary treatment of cystosarcoma phyllodes of the breast. Cancer 89:1502–1511PubMedCrossRef
2.
3.
Bennett IC, Khan A, De Freitas R et al (1992) Phyllodes tumours: a clinicopathological review of 30 cases. Aust N Z J Surg 62:628–33
4.
Asoglu O, Ugurlu MM, Blanchard K et al (2004) Risk factors for recurrence and death after primary surgical treatment of malignant phyllodes tumors. Ann Surg Oncol 11:1011–1017PubMedCrossRef
5.
Karim RZ, Gerega SK, Yang YH et al (2009) Phyllodes tumours of the breast: a clinicopathological analysis of 65 cases from a single institution. Breast 18:165–170PubMedCrossRef
6.
Barth RJ Jr (1999) Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors. Breast Cancer Res Treat 57:291–295PubMedCrossRef
7.
Reinfuss M, Mitus J, Duda K et al (1996) The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer 77:910–916PubMedCrossRef
8.
Jara-Lazaro AR, Tan PH (2009) Molecular pathogenesis of progression and recurrence in breast phyllodes tumors. Am J Transl Res 1:23–34PubMed
9.
10.
Jacklin RK, Ridgway PF, Ziprin P et al (2006) Optimising preoperative diagnosis in phyllodes tumour of the breast. J Clin Pathol 59:454–459PubMedCrossRef
11.
Kapiris I, Nasiri N, A’Hern R et al (2001) Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast. Eur J Surg Oncol 27:723–730PubMedCrossRef
12.
Chua CL, Thomas A, Ng BK (1989) Cystosarcoma phyllodes: a review of surgical options. Surgery 105:141–147PubMed
13.
Salvadori B, Cusumano F, Del Bo R et al (1989) Surgical treatment of phyllodes tumors of the breast. Cancer 63:2532–2536PubMedCrossRef
14.
Bernstein L, Deapen D, Ross RK (1993) The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. Cancer 71:3020–3024PubMedCrossRef
15.
Mangi AA, Smith BL, Gadd MA et al. (1999) Surgical management of phyllodes tumors. Arch Surg 134:487–92 (discussion 92-3)
16.
Mokbel K, Price RK, Mostafa A et al (1999) Phyllodes tumour of the breast: a retrospective analysis of 30 cases. Breast 8:278–281PubMedCrossRef
17.
Hawkins RE, Schofield JB, Fisher C et al (1992) The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes. Cancer 69:141–147PubMedCrossRef
18.
Tse GM, Putti TC, Kung FY et al (2002) Increased p53 protein expression in malignant mammary phyllodes tumors. Mod Pathol 15:734–740PubMedCrossRef
19.
Pietruszka M, Barnes L (1978) Cystosarcoma phyllodes: a clinicopathologic analysis of 42 cases. Cancer 41:1974–1983PubMedCrossRef
20.
Contarini O, Urdaneta LF, Hagan W et al (1982) Cystosarcoma phylloides of the breast: a new therapeutic proposal. Am Surg 48:157–166PubMed
21.
Karim RZ, Scolyer RA, Tse GM et al (2009) Pathogenic mechanisms in the initiation and progression of mammary phyllodes tumours. Pathology 41:105–117PubMedCrossRef
Metadata
Title
The clinical features and prognosis of phyllodes tumors: a single institution experience in Taiwan
Authors
Chin-Chan Lin
Hui-Wen Chang
Chen-Yuan Lin
Chang-Fang Chiu
Shin-Pen Yeh
Publication date
01-08-2013
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 4/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-012-0442-4

Other articles of this Issue 4/2013

International Journal of Clinical Oncology 4/2013 Go to the issue

Original Article

Low microvascular density at the tumor center is related to the expression of metalloproteases and their inhibitors and with the occurrence of distant metastasis in breast carcinomas

Original Article

Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer

Original Article

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

Original Article

Is extracapsular tumour spread a prognostic factor in patients with early breast cancer?

Original Article

Role of CD44 expression in non-tumor tissue on intrahepatic recurrence of hepatocellular carcinoma

Original Article

Treatment outcome of patients with extragonadal nonseminomatous germ cell tumors: the Saitama Cancer Center experience
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits